by Clare Gerrard | Jul 17, 2023
The Big Cancer52 Conversation on Wednesday 14th June brought together leaders from the charity, healthcare and pharmaceutical sectors, to share best practices, exchange ideas and explore collaborations, with the ultimate aim of improving outcomes for people with rare...
by Clare Gerrard | Jan 31, 2023
Winner of Neuroendocrine Cancer UK’s £30,000 grant for research Dr Garan Jones, the University of Exeter – “Our research project is titled “Determining the role of alternate splicing in the development of Small Intestine Neuroendocrine tumours...
by Clare Gerrard | Jan 30, 2023
In medicine, the term “zebra” is used in reference to a rare disease or condition. “If you hear hooves, you assume horse.” The rare disease community wants you to consider zebra. We agree with and advocate this message. However due to the rise in incidence of...
by Clare Gerrard | Nov 14, 2022
We advocate for the establishment of a stable UK supply of radionuclides for health and medical use. Our main focus is on the use of radionuclides in innovative cancer treatments such as molecular radiotherapy (i.e. the injection of radioactive substances for...
by Leanne Talbot | Oct 26, 2021
Monday 25th October saw the launch of the NHS Cancer Quality of Life Survey data dashboard. The survey is for people in England who have been diagnosed with cancer. From 2020, people who have had a breast, prostate or colorectal (bowel) cancer diagnosis are being...